Targeting delivery of oligonucleotide and plasmid DNA to hepatocyte via galactosylated chitosan vector

被引:74
作者
Gao, SY
Chen, JN
Dong, L
Ding, Z
Yang, YH
Zhang, JF [1 ]
机构
[1] Nanjing Univ, Dept Biochem, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Peoples R China
[2] Nanjing Univ, Jiangsu Prov Lab Nanotechnol, Nanjing 210093, Peoples R China
基金
中国国家自然科学基金;
关键词
galactosylated low molecular weight chitosan; plasmid DNA; antisense oligonucleotide; hepatocyte targeting; transfection efficiency; non-viral vector;
D O I
10.1016/j.ejpb.2005.02.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Delivery of oligonucleotide, to specific cells and maintenance of its biological function are important for nucleic acid therapy. The objective of this paper is to demonstrate that galactosylated low molecular weight chitosan (gal-LMWC) is a safe and effective vector of antisense oligonucleotide (ASO) and plasmid DNA for the hepatocyte targeting delivery. Gal-LMWC has been successfully prepared and MTT cytotoxic assay shows that cytotoxicity of gal-LMWC is lower than that of high molecular weight chitosan (HMWC) and low molecular weight chitosan (LMWC) in HepG2 cells. Using a complex coacervation process, gal-LMWC can form stable nano-complexes with plasmid DNA or with ASO by the electrostatic interaction. The morphometrics, particle size, and the zeta potential of gal-LMWC/ASO complexes and gal-LMWC/plasmid DNA complexes are very similar. The transfection efficiency by using gal-LMWC vector is significantly higher than that of naked DNA or naked ASO in HepG2 cells. Transfection efficiency of gal-LMWC/ASO complexes and gal-LMWC/plasmid DNA complexes depends on the molar ratio of the positive chitosan amino group and the negative DNA phosphate group (N/P ratio) strongly. Inhibition experiments confirm that the enhanced transfection efficiency is due to the ASGR mediated endocytosis of the gal-LMWC/ASO complexes or gal-LMWC/DNA complexes. These results suggest that gal-LMWC can be used in gene therapy to improve the transfection efficiency in vitro and in vivo. (c) 2005 Published by Elsevier B.V.
引用
收藏
页码:327 / 334
页数:8
相关论文
共 33 条
[1]  
BERSCH PC, 1995, J MAT SCI MED, V6, P231
[2]   The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides [J].
Chirila, TV ;
Rakoczy, PE ;
Garrett, KL ;
Lou, X ;
Constable, IJ .
BIOMATERIALS, 2002, 23 (02) :321-342
[3]   Chitosan-based nanoparticles for topical genetic immunization [J].
Cui, ZR ;
Mumper, RJ .
JOURNAL OF CONTROLLED RELEASE, 2001, 75 (03) :409-419
[4]   Pharmaceutical applications of chitosan [J].
Dodane, V ;
Vilivalam, VD .
PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1998, 1 (06) :246-253
[5]   Chitosan-based vector/DNA complexes for gene delivery: Biophysical characteristics and transfection ability [J].
Erbacher, P ;
Zou, SM ;
Bettinger, T ;
Steffan, AM ;
Remy, JS .
PHARMACEUTICAL RESEARCH, 1998, 15 (09) :1332-1339
[6]   Gene therapy: Safer and virus-free? [J].
Ferber, D .
SCIENCE, 2001, 294 (5547) :1638-1642
[7]   Alginate/poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides [J].
Ferreiro, MG ;
Tillman, LG ;
Hardee, G ;
Bodmeier, R .
PHARMACEUTICAL RESEARCH, 2002, 19 (06) :755-764
[8]   Galactosylated low molecular weight chitosan as DNA carrier for hepatocyte-targeting [J].
Gao, SY ;
Chen, JN ;
Xu, XR ;
Ding, Z ;
Yang, YH ;
Hua, ZC ;
Zhang, JF .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 255 (1-2) :57-68
[9]  
GUMMOW BD, 1985, MAKROMOL CHEM, V186, P1239
[10]  
HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101